Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards

Boehringer to settle thousands of cases that allege Pradaxa bleeding risk

By Brian Buntz | November 11, 2020

Boehringer IngelheimBoehringer Ingelheim has reached an agreement in principle to settle some 2,935 lawsuits tied to its blood thinner Pradaxa (dabigatran etexilate). 

In a Connecticut Supreme Court filing, privately owned Boehringer (Ingelheim am Rhein, Germany) stated the settlement would resolve the lawsuits, which alleged the anticoagulant drug Pradaxa caused undisclosed bleeding risks.

The company expects it will take six to nine months to know if plaintiffs will accept the settlement. 

Boehringer asked for a stay in two cases until the parties in those cases either accept or reject the finalized settlement.  

Plaintiffs have filed 2,865 of the lawsuits in the Judicial District of Hartford as part of a complex litigation docket. 

In related news, Boehringer has asked the 4th U.S. Circuit Court of Appeals to stay its appeal of another Pradaxa lawsuit that concluded with a $1.25 million jury award. 

In the years that followed FDA approval of Pradaxa, plaintiffs have filed thousands of liability lawsuits against Boehringer. 

Pradaxa is a newer alternative to traditional blood thinners, such as warfarin. Competitors include Xarelto from Johnson & Johnson (NYSE: JNJ) and Eliquis, which Pfizer (NYSE: PFE) and Bristol Myers Squibb (NYSE: BMY) have jointly marketed. Such blood thinners can reduce the risk of stroke for patients with atrial fibrillation. FDA approved the drug in 2010. 

 

 

Tell Us What You Think! Cancel reply

Related Articles Read More >

HIV
Injectable anti-HIV therapies could see strong growth
Pfizer-BioNTech vaccine
Pfizer vaccine stable at standard freezer temps, effective with single dose
coronavirus COVID-19 Pfizer
4 things to keep in mind as COVID-19 vaccination efforts scale
Johnson & Johnson
J&J CEO says getting a COVID-19 vaccine could be an annual ritual for years

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Pharmaceutical Processing World
  • Enews Signup
  • Contact Us
  • About Us
  • R&D World
  • DeviceTalks
  • Drug Discovery & Development
  • Drug Delivery Business News
  • MassDevice
  • Medical Design Sourcing

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards